Copyright
©2014 Baishideng Publishing Group Co.
World J Gastroenterol. Mar 7, 2014; 20(9): 2143-2158
Published online Mar 7, 2014. doi: 10.3748/wjg.v20.i9.2143
Published online Mar 7, 2014. doi: 10.3748/wjg.v20.i9.2143
Table 3 Published randomized controlled trials of pentoxifylline vs placebo for severe alcoholic hepatitis n (%)
Ref. | n | Duration of treatment with pentoxifylline 400 mg PO tid | Mortality in placebo | Mortality in pentoxifylline | Relative risk or hazard ratio | 95%CI | Comments |
Akriviadis et al[110], 2000 | 101 | 28 d | 24/52 (46) | 12/49 (24) | RR = 0.59 | 0.35-0.97 | Positive study (P = 0.037) |
Fernández-Rodríguez et al[112], 2008 | 24 | 28 d | Not reported1 | Not reported1 | HR = 1.46 | 0.5-4.28 | Negative study (P = 0.48) |
Tyagi et al[107], 2011 | 612 | 6 mo | 2/31 (6) | 1/30 (3) | Not reported | Not reported | Negative study2 (P = 0.15) |
Sidhu et al[109], 2012 | 50 | 28 d | 10/25 (40) | 5/25 (20) | RR = 0.5 | 0.19-1.25 | Negative study (P = 0.216) |
- Citation: Jaurigue MM, Cappell MS. Therapy for alcoholic liver disease. World J Gastroenterol 2014; 20(9): 2143-2158
- URL: https://www.wjgnet.com/1007-9327/full/v20/i9/2143.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i9.2143